Investor Relations

This financial calendar lists the expected release dates of Ambu’s financial announcements for the financial year 2026/27, as well as the date of Ambu’s Annual General Meeting. 
 

Deadline for the inclusion of specific items on the agenda for the Annual General Meeting 2026 is 20 October 2026.

Download the company announcement here.

Current Grifols CEO and former Olympus executive, Nacho Abia, brings more than 20 years of leadership experience across global healthcare and endoscopy.

Copenhagen, Denmark, 28 September 2026 – Ambu, the global market leader in single-use endoscopy, today announces that Jose Ignacio (Nacho) Abia Buenache has been appointed as an observer to Ambu’s Board of Directors and will be proposed for election as a member of the Board at the Company’s upcoming annual general meeting on 2 December 2026.

Nacho Abia currently serves as Chief Executive Officer and member of the Board of Directors of Grifols, a global pharmaceutical company with annual revenue exceeding EUR 7 billion.

Prior to joining Grifols in 2024, Abia spent more than two decades at Olympus Corporation, where he held several senior executive positions, including Global Chief Operating Officer, Chief Executive Officer of Olympus Americas, and Global Chief Strategy Officer.

“I am excited to welcome Nacho Abia as a board observer to Ambu’s Board of Directors,” says Jørgen Jensen, Chair of Ambu’s Board of Directors. “Nacho brings a strong combination of global healthcare leadership, endoscopy knowledge, and a proven track record of driving innovation, execution, and growth. His experience will be a significant asset to the Board as we continue to realize Ambu's substantial long-term potential.”

“Ambu is a pioneer in single-use endoscopy and has demonstrated how innovation, a strong culture, and close collaboration with clinicians can challenge established practices and create meaningful value for healthcare professionals and patients,” says Nacho Abia. “I believe Ambu is uniquely positioned to continue advancing endoscopy and expand the impact of single-use solutions globally. The company has a strong foundation, a clear strategic direction, and significant opportunities ahead. I look forward to working closely with the Board and Executive Management to support Ambu's continued growth and help shape the evolution of endoscopy.”

Read the press release here.

With an expanded indication for sigmoidoscopy procedures, Ambu^® aScope™ Gastro and Ambu^® aScope™ Gastro Large are the first single-use GI endoscopy solutions indicated for both upper and lower GI procedures, nearly doubling Ambu’s procedure reach in GI.

Ballerup, Denmark, 25 September 2026 – Ambu, the global market leader in single-use endoscopy, today announces that its two gastrointestinal (GI) endoscopy solutions, Ambu aScope Gastro and Ambu aScope Gastro Large, have received FDA 510(k) clearance and CE mark for an expanded indication covering flexible sigmoidoscopy procedures in the lower GI tract.

Since their launches in 2022 and 2024, aScope Gastro and aScope Gastro Large have supported intraoperative endoscopy during upper GI surgery, as well as bedside procedures for diagnosis and management of upper GI bleeding. With the expanded indication, aScope Gastro and aScope Gastro Large can now also be used for flexible sigmoidoscopy procedures, including intraoperative GI endoscopy during colorectal surgery as well as lower GI bleeds in the sigmoid colon and rectum.

This expands the use of Ambu's single-use GI endoscopy solutions across both upper and lower GI care in the operating room and bedside environments in the intensive care unit. As a result, Ambu becomes the first provider of single-use GI endoscopes with dual regulatory clearance for both upper GI and lower GI procedures, while also nearly doubling the amount of procedures the Company can target.

Flexible sigmoidoscopy is a minimally invasive procedure used to examine the lower colon and rectum. During colorectal surgery specifically, it can help assess the surgical connection and identify potential complications. With the expanded indication, Ambu can offer single-use GI endoscopes that are available when needed for both upper and lower GI procedures, supporting simpler workflows and greater procedural flexibility.

GI represents the largest area of the global endoscopy market, with single-use adoption remaining in the early stages. For Ambu, GI is a long-term growth opportunity, and the expanded indication reflects Ambu’s stepwise approach to broadening its GI offering, in line with the Company’s ZOOM AHEAD strategy.

“GI is an important long-term growth opportunity for Ambu, and while single-use adoption in this area is still at an early stage, we are building our presence through a stepwise approach,” says Britt Meelby Jensen, CEO of Ambu. “With our GI endoscopy platform cleared for both upper and lower GI procedures, we are strengthening our clinical relevance, and, more broadly, taking another focused step toward our ambition to achieve global endoscopy leadership.”

Ambu expects to commercially launch its GI solutions across the U.S. and Europe in early 2027 with updated Instructions For Use (IFUs) reflecting the expanded indication.

Read the full press release here.